|  |  | Number of | Incidence of events (%) |  |  | ||
---|---|---|---|---|---|---|---|---|
Outcome and comparisons | Celecoxib daily dose | Comparator and daily dose | Trials | Patients | Celecoxib | Comparator | Relative riska (95% CI) | NNTpb or NNHc (95% CI) |
All-cause discontinuation | Â | Â | Â | Â | Â | Â | Â | Â |
Celecoxib v placebo | Any | Placebo | 19 | 9,919 | 28 | 40 | 0.64 (0.61–0.68) a | 8.4 (7–10) b |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 17 | 25 | 0.69 (0.54–0.88) a | 13 (8–35) b |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 14 | 14 | 1.0 (0.8–1.2) |  |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,616 | 23 | 23 | 0.96 (0.91–1.01) |  |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,711 | 31 | 34 | 0.96 (0.93–0.99) a | 28 (22–40) b |
Celecoxib (any dose) v any active | Any | Any active comparator | 26 | 35,302 | 29 | 32 | 0.95 (0.92–0.98) a | 36 (27–57) b |
Lack-of-efficacy discontinuation | Â | Â | Â | Â | Â | Â | Â | |
Celecoxib v placebo | Any | Placebo | 19 | 9,914 | 17 | 28 | 0.53 (0.49–0.57) a | 9.0 (8–11) b |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 7.2 | 11 | 0.66 (0.45–0.97) a | 27 (14–390) b |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 2.2 | 1.5 | 1.5 (0.84–2.6) |  |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,613 | 8.0 | 6.3 | 1.1 (1.02–1.23) a | 58 (42–97)c |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,708 | 11.3 | 10.4 | 1.02 (0.96–1.1) |  |
Celecoxib (any dose) v any active | Any | Any active comparator | 26 | 35,299 | 10.6 | 9.6 | 1.0 (0.95–1.1) |  |
Adverse-event discontinuation | Â | Â | Â | Â | Â | Â | Â | Â |
Celecoxib v placebo | Any | Placebo | 19 | 9,914 | 6.6 | 5.5 | 1.2 (0.97–1.4) |  |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 1,056 | 4.3 | 5.4 | 0.81 (0.47–1.4) |  |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,662 | 6.2 | 6.8 | 0.91 (0.68–1.2) |  |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 19 | 22,613 | 8.5 | 9.9 | 0.84 (0.77–0.92) a | 74 (47–180) b |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 20 | 31,708 | 11.4 | 14.6 | 0.86 (0.81–0.91) a | 31 (25–41) b |
Celecoxib (any dose) v any active | Any | Any active comparator | 26 | 35,299 | 10.9 | 13.5 | 0.87 (0.82–0.92) a | 38 (30–51) b |
Gastrointestinal-adverse-event discontinuation | Â | Â | Â | Â | Â | Â | ||
Celecoxib v placebo | Any | Placebo | 11 | 5,933 | 2.5 | 2.0 | 1.2 (0.8–1.7) |  |
Celecoxib v paracetamol | Any | Paracetamol 4,000 mg | 2 | 726 | 1.6 | 2.6 | 0.6 (0.2–1.6) |  |
Celecoxib v rofecoxib | Any | Rofecoxib 25 mg | 5 | 2,671 | 2.2 | 2.9 | 0.7 (0.5–1.2) |  |
Celecoxib (200/400) v NSAID | 200–400 mg | NSAID to maximum daily | 11 | 18,639 | 4.8 | 6.5 | 0.7 (0.6–0.8) a | 58 (42–98) b |
Celecoxib (any dose) v NSAID | Any | NSAID to maximum daily | 12 | 27,299 | 6.4 | 9.6 | 0.75 (0.7–0.8) a | 31 (26–40) b |
Celecoxib (any dose) v any active | Any | Any active comparator | 18 | 30,560 | 6 | 8.7 | 0.75 (0.7–0.8) a | 37 (30–48) b |